The role and advances of immunomodulator therapy for inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 2, 2015, Pages 177-189

  Nielsen, Ole Haagen ^a   Coskun, Mehmet ^a   Steenholdt, Casper ^a   Rogler, Gerhard ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

6 mercaptopurine; azathioprine; Crohn's disease; inflammatory bowel disease; methotrexate; therapy; ulcerative colitis

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; FOLIC ACID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; IMMUNOLOGIC FACTOR;

ALLERGIC PNEUMONITIS; AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ASSAY; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOTHERAPY; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NON MELANOMA SKIN CANCER; PANCREATITIS; PANCREATOXICITY; POSTOPERATIVE CARE; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REVIEW; T CELL LYMPHOMA; TOXICITY; ULCERATIVE COLITIS; VITAMIN SUPPLEMENTATION; VOMITING; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

6-MERCAPTOPURINE; AZATHIOPRINE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; METHOTREXATE; TREATMENT OUTCOME;

EID: 84921327156     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.945914     Document Type: Review

References (153)

1. Hitchings GH, Elion GB. The chemistry and biochemistry of purine analogs. Ann N Y Acad Sci 1954;60(2):195-9
2. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohns disease with 6-mercaptopurine. A long-Term, randomized, double-blind study. N Engl J Med 1980;302(18):981-7
3. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001;8(2):123-43
4. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110(5):353-6
5. Domenech E, Nos P, Papo M, et al. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol 2005;40(1):52-5
6. McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002;122(3):838-9
7. Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol 2013;53(6): 575-88
8. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006;24(5):715-29
9. Neurath MF, Kiesslich R, Teichgraber U, et al. 6-Thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohns disease. Clin Gastroenterol Hepatol 2005;3(10):1007-14
10. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):935-9
11. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment;a pharmacogenomic test whose time has come. J Clin Pathol 2010;63(4):288-95
12. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89(3):387-91
13. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013;93(4):324-5
14. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6(10): 991-1030
15. Dignass A, Van AG, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: current management. J Crohns Colitis 2010;4(1):28-62
16. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60(5):571-607
17. Lennard L. TPMT in the treatment of Crohns disease with azathioprine. Gut 2002;51(2):143-6
18. Thompson AJ, Newman WG, Elliott RA, et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health 2014;17(1): 22-33
19. Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine s-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011;154(12):814-23
20. Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011;17(6): 1301-7
21. Moreau AC, Paul S, Del TE, et al. Association between 6-Thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-Analysis. Inflamm Bowel Dis 2014;20(3):464-71
22. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, et al. Thiopurine methyl-Transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-Treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011;34(5):544-54
23. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49(5):665-70
24. Reinshagen M, Schutz E, Armstrong VW, et al. 6-Thioguanine nucleotide-Adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53(7):1306-14
25. Chouchana L, Narjoz C, Beaune P, et al. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35(1):15-36
26. Ansari A, Elliott T, Baburajan B, et al. Long-Term outcome of using allopurinol co-Therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008;28(6):734-41
27. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005;22(5):441-6
28. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5(2):209-14
29. Sparrow MP. IBD: switching metabolism-can two drugs be better than one?. Nat Rev Gastroenterol Hepatol 2010;7(8):420-2
30. Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012;6(9):905-12
31. Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf 2008;7(5):607-16
32. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985;28(1):77-102
33. Morgan SL, Oster RA, Lee JY, et al. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-Treated rheumatoid arthritis. Arthritis Rheum 2004;50(10):3104-11
34. Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003;42(2):139-51
35. Jacobs SA, Adamson RH, Chabner BA, et al. Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexate, 4-Amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate. Biochem Biophys Res Commun 1975;63(3):692-8
36. Louis E, ElYafi FAN, Belaiche J. High doses of azathioprine but not 6-mercaptopurine inhibit the production of pro-inflammatory cytokines in inflammatory bowel diseases: an in vitro study. Gastroenterology 2000;118(Suppl 2):4204
37. Almer S. Novel strategies in the thiopurine treatment of inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 2010;29(4-6):267-77
38. Chande N, Tsoulis DJ, Macdonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohns disease. Cochrane Database Syst Rev 2013;4: CD000545
39. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-Alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohns disease. Gastroenterology 2013;145(6):1464-78
40. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-Alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohns disease. Gastroenterology 2013;145(6):1459-63
41. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2009(1):CD000067
42. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohns disease. Gut 1995;37(5):674-8
43. DHaens GR, Vermeire S, Van AG, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohns disease: a controlled randomized trial. Gastroenterology 2008;135(4):1123-9
44. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohns disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127(3):723-9
45. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohns disease patients in long-Term remission on azathioprine. Gastroenterology 2005;128(7):1812-18
46. ODonoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohns disease. Lancet 1978;2(8097):955-7
47. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohns disease. Am J Dig Dis 1975;20(8):721-6
48. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohns Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847-69
49. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohns disease. Lancet 1971;2(7731):944-7
50. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohns Disease: a randomized controlled trial. Gastroenterology 2013;145(4):758-65
51. Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohns disease. Gastroenterology 2013;145(4):766-74
52. de Boer NK, van Bodegraven AA. Get the best out of thiopurine therapy. Gastroenterology 2014;146(3):865
53. Hawthorne AB, Probert CS, Sanderson JD. Early use of azathioprine in Crohns disease. Gastroenterology 2014;146(3):865-6
54. Lakatos PL, Peyrin-Biroulet L. Azathioprine in Early Crohns Disease: Time to Revisit Patient Selection and End Points for Clinical Trials And/or Azathioprine Efficacy?. Gastroenterology 2014;146(3):867-8
55. Rammohan H, Pai CG. Shrinking indications for azathioprine in Crohns disease: a conclusion too premature?. Gastroenterology 2014;146(3):866-7
56. Jones GR, Kennedy NA, Lees CW, et al. Systematic review: the use of thiopurines or anti-TNF in post-operative Crohns disease maintenance - progress and prospects. Aliment Pharmacol Ther 2014;39(11): 1253-65
57. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohns disease: a meta-Analysis. Am J Gastroenterol 2009;104(8):2089-96
58. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohns disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59(6):752-9
59. Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohns disease: a systematic review and meta-Analysis. Am J Gastroenterol 2014;109(1):23-34
60. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohns disease?. Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012;107(4):579-88
61. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohns disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59(9):1200-6
62. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974;4(5945): 627-30
63. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000;19(1):14-16
64. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-Analysis. Am J Gastroenterol 2011;106(4):630-42
65. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9:CD000478
66. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-Aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55(1):47-53
67. McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohns disease. Cochrane Database Syst Rev 2012;12: CD003459
68. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohns disease. North American Crohns Study Group Investigators. N Engl J Med 2000;342(22):1627-32
69. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12(11):1227-33
70. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohns disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92(12):2203-9
71. Patel V, Macdonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2009(4):CD006884
72. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110(5):1416-21
73. Chande N, Macdonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007(4):CD006618
74. Herfarth HH, Osterman MT, Isaacs KL, et al. Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis 2010;16(8):1421-30
75. Comparison of methotrexate vs placebo in steroid-refractory ulcerative colitis (METEOR). Available from: http://clinicaltrials.gov/show/NCT00498589
76. Methotrexate in induction and maintenance of steroid free remission in ulcerative colitis (Merit-UC). Available from: http://clinicaltrials.gov/show/NCT01393405
77. Onuk MD, Kaymakoglu S, Demir K. Low-dosage weekly methotrexate therapy in remission maintenance in ulcerative colitis. Gut 1996;39:A75
78. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013;369(8): 754-62
79. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. Gut 2007;56(9):1181-3
80. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohns disease in adults. Am J Gastroenterol 2009;104(2):465-83
81. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohns disease: current management. Gut 2006;55(Suppl 1):i16-35
82. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-Tumor necrosis factor and immunomodulator therapy for the treatment of Crohns disease: a meta-Analysis. Clin Gastroenterol Hepatol 2009;7(8):874-81
83. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohns and Colitis Organisation: safety. Am J Gastroenterol 2011;106(9): 1594-602
84. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohns disease: results from the TREAT Registry. Am J Gastroenterol 2014;109(2):212-23
85. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013;108(12):1835-42.quiz
86. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohns disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130(4):1054-61
87. DHaens G, Baert F, Van AG, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomised trial. Lancet 2008;371(9613): 660-7
88. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010;362(15):1383-95
89. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146(2):392-400
90. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-Term efficacy of infliximab in Crohns disease. N Engl J Med 2003;348(7):601-8
91. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-Analysis. Am J Gastroenterol 2013;108(1):40-7
92. Vermeire S, Noman M, Van AG, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohns disease. Gut 2007;56(9):1226-31
93. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohns disease. Gastroenterology 2014;146(3):681-8
94. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial. Gastroenterology 2007;132(1):52-65
95. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
96. Moss AC, Kim KJ, Fernandez-Becker N, et al. Impact of concomitant immunomodulator use on long-Term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci 2010;55(5):1413-20
97. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004;350(9):876-85
98. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-Treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59(10):1363-8
99. Armuzzi A, Pugliese D, Danese S, et al. Long-Term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014. [Epub ahead of print
100. McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8(3): 223-40
101. Thomas A, Lodhia N. Advanced therapy for inflammatory bowel disease: a guide for the primary care physician. J Am Board Fam Med 2014;27(3):411-20
102. Salliot C, van der HD. Long-Term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68(7): 1100-4
103. Kane S. Preparing the patient for immunosuppressive therapy. Curr Gastroenterol Rep 2010;12(6):502-6
104. Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006;24(2):331-42
105. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohns disease. Cochrane Database Syst Rev 2009(4):CD000545
106. Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-Analysis. Aliment Pharmacol Ther 2013;38(10): 1255-66
107. Kennedy NA, Lees CW. Azathioprine-induced pancreatitis and subsequent tolerance of mercaptopurine. Aliment Pharmacol Ther 2014;39(4):440-1
108. Shih DQ, Nguyen M, Zheng L, et al. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012;36(5):449-58
109. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-Term follow-up study of 3931 patients. Inflamm Bowel Dis 2013;19(7):1404-10
110. Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2005;39(1):21-6
111. de Boer NK, van Bodegraven AA, Jharap B, et al. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4(12):686-94
112. Grassia R, Paolo CG, Staiano T. Severe muscular weakness as an isolated symptom of azathioprine hypersensitivity. Inflamm Bowel Dis 2011;17(6):E61
113. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- And long-Term toxicity. Ann Intern Med 1989;111(8):641-9
114. Connell WR, Kamm MA, Dickson M, et al. Long-Term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343(8908): 1249-52
115. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118(4):705-13
116. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohns disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118(6):1025-30
117. Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease?. Therap Adv Gastroenterol 2010;3(1):31-42
118. Gluck T, Kiefmann B, Grohmann M, et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005;32(8):1473-80
119. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349(5):474-85
120. Bokemeyer B. Asymptomatic elevation of serum lipase and amylase in conjunction with Crohns disease and ulcerative colitis. Z Gastroenterol 2002;40(1):5-10
121. Floyd A, Pedersen L, Nielsen GL, et al. Risk of acute pancreatitis in users of azathioprine: a population-based casecontrol study. Am J Gastroenterol 2003;98(6):1305-8
122. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohns disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/ mercaptopurine. Aliment Pharmacol Ther 2009;30(6):614-20
123. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- And long-Term toxicity to 6-mercaptopurine in the treatment of Crohns disease and ulcerative colitis. J Clin Gastroenterol 2003;37(3):220-5
124. Vernier-Massouille G, Cosnes J, Lemann M , et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007;56(10): 1404-9
125. Seiderer J, Zech CJ, Diebold J, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006;18(5):553-5
126. Khan N, Abbas AM, Whang N, et al. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-Analysis of clinical trials. Inflamm Bowel Dis 2012;18(2): 359-67
127. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of Lymphoma in Patients with Inflammatory Bowel Disease Treated with Azathioprine and 6-Mercaptopurine: a Meta-Analysis. Clin Gastroenterol Hepatol 2014. [Epub ahead of print
128. Kotlyar DS, Gisbert JP, Lewis JD, et al. Overall incidence of hepatosplenic T cell lymphoma in patients with inflammatory bowel disease on thiopurines. Gastroenterology 2011;140:S775
129. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9(1):36-41
130. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121-5
131. Kotlyar D, Gisbert J, Chaparro M, et al. Systematic review: Duration of exposure to azathiopurine/6-mercaptopurine as a risk factor for lymphoma. Gastroenterology 2012;142(Suppl 1):S250
132. Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18(11):2063-71
133. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010;105(7):1604-9
134. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701): 1617-25
135. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2010;17:1837-45
136. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58(10):1427-36
137. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-Analysis. Am J Gastroenterol 2014;109(2):163-9
138. Beigel F, Steinborn A, Schnitzler F, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014. [Epub ahead of print
139. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014;8(1): 31-44
140. Hsiao SC, Ichinohasama R, Lin SH, et al. EBV-Associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate. Pathol Res Pract 2009;205(1): 43-9
141. French H, Mark DA, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohns disease: a meta-Analysis. Dig Dis Sci 2011;56(7): 1929-36
142. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50(4):485-9
143. Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Optimum duration of treatment with 6-mercaptopurine for Crohns disease. Am J Gastroenterol 1999;94(11):3254-7
144. Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004;99(3):462-5
145. Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012;18: 174-9
146. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305(6844):20-2
147. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009;104(11):2760-7
148. Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol 2010;105(7):1620-6
149. Hawthorne AB. Methotrexate: a useful alternative in Crohns disease?. Gut 2001;49(1):9-10
150. Rogler G, Sandborn WJ. Is there still a role for thiopurines in Crohns disease?. Gastroenterology 2013;145(4):714-16
151. Narula N, Peyrin-Biroulet L, Colombel JF. Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?. Gastroenterology 2014;146(3): 608-11
152. Pedersen J, Coskun M, Soendergaard C, et al. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014;20(1): 64-77
153. Mosli MH, Sandborn WJ, Kim RB, et al. Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. Am J Gastroenterol 2014. [Epub ahead of print